RecruitingPhase 4NCT06901245

Tirzepatide in PWS, HO and GNSO

The Effects of Tirzepatide in Young Adults With Prader-Willi Syndrome, Hypothalamic Obesity and General Non-Syndromic Obesity

Sponsor

Grace Kim

Enrollment

36 participants

Start Date

May 1, 2025

Study Type

INTERVENTIONAL

Conditions

Prader-Willi Syndrome Hypothalamic Obesity Obesity/Therapy

Summary

This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.

Eligibility

Min Age: 18 YearsMax Age: 26 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Tirzepatide for people with hypothalamic obesity, obesity/therapy, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 26 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.